BREA,
Calif., July 25, 2024 /PRNewswire/ -- Beckman
Coulter Diagnostics, a clinical diagnostics leader, today announced
that the DxI 9000 Immunoassay Analyzer* was honored during Premier,
Inc.'s annual supplier Innovation Celebration at its 2024
Breakthroughs Conference and Exhibition. The Innovation Celebration
recognizes groundbreaking healthcare technologies that have been
launched throughout the year and the ways these products are
helping to improve the health of communities.
With the highest throughput compared to any immunoassay analyzer
on the market, Beckman Coulter's DxI 9000 Immunoassay Analyzer is
filled with novel and innovative technologies with safeguards to
prevent errors that could impact patient results, turnaround times,
and costly errors. Furthermore the system delivers the highest
percentage of Six Sigma assays on the market.
A transformative feature of the DxI 9000 Immunoassay analyzer is
the Lumi-Phos PRO substrate which allows for a new standard in
analytical sensitivity. Using this substrate, analytes can be
measured at the attomole level which is the equivalent of a
teaspoon of sugar in 100,000 Olympic-sized swimming pools. This
analytical sensitivity opens the door to venture into complementary
diagnostics in disease states with unmet needs or revisions of
claims for established assays for new clinical use cases.
"Premier's supplier Innovation Celebration is a remarkable
event, showcasing the pinnacle of ingenuity within the healthcare
industry," said Kathleen Orland,
Senior Vice President, Clinical Chemistry and Immunoassay General
Manager, Beckman Coulter Diagnostics. "The celebration highlights
transformative solutions that enhance patient care, streamline
operations, and drive overall efficiency. Premier's dedication to
recognizing these contributions elevates industry standards while
encouraging continuous improvement and creative problem-solving,
ultimately benefiting patients and healthcare providers alike."
"Premier proudly acknowledges Beckman Coulter's outstanding
commitment to advancing healthcare," said Bruce Radcliff, Senior Vice President, Supply
Chain at Premier. "Recognizing the DxI 9000 Analyzer at our 2024
Innovation Celebration reflects our shared mission to drive
cost-efficiency, operational excellence and improved patient
outcomes. We applaud Beckman Coulter for its invaluable
contributions to healthcare."
Beckman Coulter was formally recognized on July 23, 2024,at Premier's annual Breakthroughs
Conference and Exhibition. Premier, Inc. is a leading
healthcare improvement and technology company that unites an
alliance of more than 4,350 U.S. hospitals and health systems and
approximately 300,000 other providers and organizations.
Follow and connect with Beckman Coulter
via LinkedIn, Twitter, and Facebook
About Beckman Coulter. Inc.
A global leader in advanced diagnostics, Beckman
Coulter has challenged convention to elevate the diagnostic
laboratory's role in improving patient health for more than 80
years. Our mission is to Relentlessly Reimagine Healthcare, One
Diagnosis at a Time – and we do this by applying the power of
science, technology and the passion and creativity of our teams.
Our diagnostic solutions are used in complex clinical testing, and
are found in hospitals, reference laboratories and physician office
settings around the globe. We exist to deliver smarter, faster
diagnostic solutions that move the needle forward from what's now
to what's next. We do this by accelerating care with an extensive
clinical menu, scalable lab automation technologies, insightful
clinical informatics, and optimize lab performance services.
Beckman Coulter is part of the Danaher Corporation (NYSE: DHR)
family of global science and technology companies. Headquartered in
Brea, Calif., it has more than
11,000 global team members.
© 2024 Beckman Coulter. All rights reserved. Beckman Coulter,
the stylized logo, and the Beckman Coulter product and service
marks mentioned herein are trademarks or registered trademarks of
Beckman Coulter, Inc. in the United
States and other countries. Lumigen and the Lumigen product
marks mentioned herein are trademarks or registered trademarks of
Lumigen, Inc. in the United States
and other countries. Lumigen is a Beckman Coulter company. The
Danaher trademark is a proprietary mark of Danaher Corporation.
MAPSS 2024-13169. The Danaher trademark is a proprietary mark of
Danaher Corporation.
*Full name DxI 9000 Access Immunoassay Analyzer
View original content to download
multimedia:https://www.prnewswire.com/news-releases/beckman-coulters-dxi-9000-immunoassay-analyzer-honored-at-premier-incs-annual-supplier-innovation-celebration-302206582.html
SOURCE Beckman Coulter Diagnostics
